Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.4436
+0.0212 (5.02%)
At close: May 22, 2026, 4:00 PM EDT
0.4512
+0.0076 (1.71%)
Pre-market: May 26, 2026, 4:02 AM EDT
Werewolf Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
39
Market Cap
21.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.89M | -18.06M | -90.55% |
| Dec 31, 2023 | 19.94M | 3.54M | 21.60% |
| Dec 31, 2022 | 16.40M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curis | 7.06M |
| Marker Therapeutics | 3.55M |
| Traws Pharma | 2.73M |
| Pluri | 1.08M |
| VYNE Therapeutics | 454.00K |
HOWL News
- 18 days ago - Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 18 days ago - Werewolf Therapeutics Quarterly report: Q1 2026 - Filings
- 18 days ago - Werewolf Therapeutics Earnings release: Q1 2026 - Filings
- 2 months ago - Werewolf Therapeutics hires Piper Sandler to assist in strategic evaluation - TheFly
- 2 months ago - Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c) - TheFly
- 2 months ago - Werewolf Therapeutics to explore range of strategic alternatives - TheFly
- 2 months ago - Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Annual report: Q4 2025 - Filings